- Conditions
- Knee Osteoarthritis
- Interventions
- PTP-01, Placebo control / saline vehicle
- Biological · Other
- Lead sponsor
- Doron Therapeutics Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Tucson, Arizona • La Mesa, California + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 49–72
of 17,795
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Metastatic Childhood Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma, Untreated Childhood Rhabdomyosarcoma
- Interventions
- Cixutumumab, Cyclophosphamide, Dactinomycin, Doxorubicin Hydrochloride, Etoposide, Ifosfamide, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Temozolomide, Vincristine Sulfate Liposome
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 49 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 121
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more
- Conditions
- Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma, Nucleophosmin 1-mutated Acute Myeloid Leukemia
- Interventions
- Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine, Quizartinib
- Drug
- Lead sponsor
- Kura Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 36 more
- Conditions
- MPOX
- Interventions
- Tecovirimat Oral Capsule, Placebo for Tecovirimat, Tecovirimat Oral Capsule (Open Label)
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 719 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 44
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 30 more
- Conditions
- Ecchymosis
- Interventions
- Petrolatum United States Pharmacopeia (USP), Vitamin K and retinol ointment, Arnica ointment, Vitamin K ointment
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 20 Years to 60 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Opioid-Related Disorders, Substance-Related Disorders
- Interventions
- Nitrous oxide 10% & placebo, Nitrous oxide 20% & placebo, Nitrous oxide 30% & placebo, Nitrous oxide 40% and placebo
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 21 Years to 32 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1996 – 1997
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- ascorbic acid, bortezomib, melphalan
- Dietary Supplement · Drug
- Lead sponsor
- Oncotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 8
- States / cities
- Fresno, California • Orange, California • West Hollywood, California + 5 more
- Conditions
- Alzheimer's Disease
- Interventions
- Aducanumab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 1,027 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 130
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 107 more
- Conditions
- Surgical Site Infection
- Interventions
- One-stage exchange joint replacement surgery, Two-stage exchange joint replacement surgery
- Procedure
- Lead sponsor
- OrthoCarolina Research Institute, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 343 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • New York, New York • Charlotte, North Carolina + 2 more
- Conditions
- Major Depressive Disorder, Insomnia
- Interventions
- SAGE-217, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 28
- States / cities
- Little Rock, Arkansas • Rogers, Arkansas • Garden Grove, California + 24 more
- Conditions
- Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
- Interventions
- gemcitabine hydrochloride, cisplatin, gefitinib, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma
- Interventions
- Larotrectinib, Larotrectinib surgical
- Drug · Procedure
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2036
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
- Conditions
- Colon Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC v8
- Interventions
- Encorafenib, Cetuximab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Patient Observation
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2034
- U.S. locations
- 202
- States / cities
- Millville, Delaware • Newark, Delaware • Rehoboth Beach, Delaware + 159 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Talactoferrin, Placebo
- Drug
- Lead sponsor
- Agennix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 742 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 29
- States / cities
- Casa Grande, Arizona • Tucson, Arizona • Aurora, Colorado + 26 more
- Conditions
- Enhanced Recovery After Surgery in a Pediatric Population
- Interventions
- Caffeine citrate 15mg/kg, 0.9% Sodium Citrate
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 3 Years to 12 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- SAR443820, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 17
- States / cities
- La Jolla, California • Los Angeles, California • Orange, California + 13 more
- Conditions
- Severe Hypertriglyceridemia
- Interventions
- Olezarsen, Placebo
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Chula Vista, California + 51 more
- Conditions
- Excessive Sleepiness
- Interventions
- Armodafinil, Matching Placebo
- Drug
- Lead sponsor
- Cephalon
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 385 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 63
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 56 more
- Conditions
- Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma, Stage IA Malignant Mesothelioma, Stage IB Malignant Mesothelioma, Stage II Malignant Mesothelioma, Stage III Malignant Mesothelioma, Stage IV Malignant Mesothelioma
- Interventions
- sorafenib tosylate, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Boston, Massachusetts
- Conditions
- Sickle Cell Disease, Sickle Cell Nephropathy
- Interventions
- Voxelotor
- Drug
- Lead sponsor
- University of Illinois Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- The Duration of Motor Block May Vary Between 12-36 Hrs
- Interventions
- Bupivacaine, Ropivacaine
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Ventral Hernia
- Interventions
- Bard Ventrio Hernia Patch
- Device
- Lead sponsor
- C. R. Bard
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 7
- States / cities
- Sacramento, California • Pensacola, Florida • Chicago, Illinois + 4 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
- Drug
- Lead sponsor
- PrECOG, LLC.
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 44
- States / cities
- Scottsdale, Arizona • Clovis, California • Los Angeles, California + 36 more
- Conditions
- Allergic Rhinitis
- Interventions
- Fluticasone furoate, Placebo Fluticasone furoate, Oxymetazoline, Placebo Oxymetazoline
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Chicago, Illinois